-
1 Comment
CytomX Therapeutics, Inc is currently in a long term downtrend where the price is trading 20.7% below its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.6.
CytomX Therapeutics, Inc's total revenue rose by 97.8% to $16M since the same quarter in the previous year.
Its net income has increased by 58.5% to $-15M since the same quarter in the previous year.
Finally, its free cash flow grew by 40.8% to $-18M since the same quarter in the previous year.
Based on the above factors, CytomX Therapeutics, Inc gets an overall score of 4/5.
None
Here's how to backtest a trading strategy or backtest a portfolio for CTMX using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
